Clinical trials: in Croatia
Arterial Ischemic Stroke
Early Doppler-Assisted Mobilization in Adults After Acute Ischemic Stroke
Post-stroke mobilization remains a subject of ongoing debate. While early mobilization-particularly the first out-of-bed mobilization-has been associated with reduced systemic complications and earlier rehabilitation, it also…
- Trial name
- DOP-MOBILIZE (NCT07232498)
- Testing
- Doppler-guided early mobilization
- Where
- 7 sites in Croatia, Portugal
- Volunteers
- 1,300 people
- Sponsor
- Unidade Local de Saúde de Coimbra, EPE
Acute Kidney Injury
Postoperative Acute Kidney Injury in Children Undergoing Major Non-cardiac Surgery
This project aims to conduct an international, prospective, multicentre, observational study to determine the incidence of Postoperative Acute Kidney Injury (PO-AKI) in hospitalized children after noncardiac surgery.
- Trial name
- POAKIDS (NCT07351149)
- Where
- 16 sites in Australia, Brazil and 8 more
- Volunteers
- 2,000 people
- Sponsor
- Uppsala University
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called GEJ cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- GLOW (NCT03653507)
- Testing
- zolbetuximab, oxaliplatin, capecitabine
- Where
- 165 sites in United States, Argentina and 16 more
- Volunteers
- 507 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Cardiovascular Risk, Chronic Kidney Disease
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation
This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with cardiovascular disease, chronic kidney disease and inflammation.
- Conditions
- Cardiovascular Risk, Chronic Kidney Disease, Inflammation
- Trial name
- ZEUS (NCT05021835)
- Testing
- Ziltivekimab B, Ziltivekimab C
- Where
- 1,073 sites in United States, Argentina and 36 more
- Volunteers
- 6,385 people
- Sponsor
- Novo Nordisk A/S
Ulcerative Colitis
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis.
- Trial name
- NCT06052059
- Testing
- IV Tulisokibart, SC Tulisokibart
- Where
- 476 sites in United States, Argentina and 43 more
- Volunteers
- 1,109 people
- Sponsor
- Merck Sharp & Dohme LLC
Wisdom Tooth Removal, Dental Anesthesia
Effect of Subperiosteal Ropivacaine After Third Molar Extraction
This study examined whether an additional injection of the long-acting local anesthetic ropivacaine at the surgical site could reduce pain and improve recovery after removal of lower wisdom teeth.
- Conditions
- Wisdom Tooth Removal, Dental Anesthesia, Ropivacaine
- Trial name
- NCT07844824
- Testing
- Ropivacaine 0.75%, Saline (0.9% NaCl)
- Where
- Croatia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Zagreb
Multiple Sclerosis
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e.
- Trial name
- NCT03599245
- Testing
- Ocrelizumab
- Where
- 161 sites in Argentina, Belgium and 24 more
- Volunteers
- 1,055 people
- Sponsor
- Hoffmann-La Roche
Relapsing Multiple Sclerosis
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
This is a study evaluating the effect of fenebrutinib on brain magnetic resonance imaging (MRI) in participants with RMS. The safety and pharmacokinetics of fenebrutinib will also be evaluated.
- Trial name
- FENopta (NCT05119569)
- Testing
- Fenebrutinib
- Where
- 17 sites in United States, Bosnia and Herzegovina and 4 more
- Volunteers
- 109 people
- Sponsor
- Hoffmann-La Roche
Crohn Disease
A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.
- Trial name
- GRAVITI (NCT05197049)
- Testing
- Guselkumab Dose 1, Guselkumab Dose 2, Guselkumab Dose 3
- Where
- 345 sites in United States, Australia and 25 more
- Volunteers
- 350 people
- Sponsor
- Janssen Research & Development, LLC
Ischemic Stroke; Ischemic Attack, Transient
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
- Trial name
- LIBREXIA-STROK (NCT05702034)
- Testing
- Milvexian
- Where
- 880 sites in United States, Argentina and 45 more
- Volunteers
- 12,523 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels.
- Trial name
- Target CD (NCT06548542)
- Testing
- Risankizumab, Lutikizumab, Trosunilimab
- Where
- 255 sites in United States, Austria and 31 more
- Volunteers
- 590 people
- Sponsor
- AbbVie
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric…
- Trial name
- NCT03958877
- Testing
- BIIB017 (peginterferon beta-1a), Interferon beta type 1a
- Where
- 65 sites in United States, Argentina and 20 more
- Volunteers
- 152 people
- Sponsor
- Biogen
Relapsing-remitting Multiple Sclerosis (RRMS)
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
The Main objectives of the study are to demonstrate pharmacokinetic (PK) similarity between ABP 692 and ocrelizumab (US), as well as between ABP 692 and ocrelizumab (EU).
- Trial name
- NCT06700343
- Testing
- Ocrelizumab (US), Ocrelizumab (EU), ABP 692
- Where
- 109 sites in United States, Belgium and 20 more
- Volunteers
- 152 people
- Sponsor
- Amgen
Right Colon Cancer
Mechanical Resistance Curves of the NTLC75 Linear Stapler During Barcelona Ileotransverse Anastomosis
This prospective single-center pilot cohort will include 40 consecutive adults undergoing elective right colectomy with a Barcelona ileotransverse anastomosis using an NTLC75/SR75 linear stapler.
- Trial name
- NTLC75-ITA (NCT07834385)
- Testing
- Passive External NTLC75 Handle-Signal Recording
- Where
- Croatia
- Volunteers
- 40 people
- Sponsor
- University Hospital of Split
Severe Hypertriglyceridemia
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to…
- Trial name
- SHASTA-5 (NCT06880770)
- Testing
- Plozasiran
- Where
- 140 sites in United States, Argentina and 25 more
- Volunteers
- 288 people
- Sponsor
- Arrowhead Pharmaceuticals
Irritant Contact Dermatitis
Glycyrrhetinic Acid and Acute Irritant Dermatitis
Irritant dermatitis is one of the most common inflammatory skin disorders, caused by exposure to external substances that induce inflammation and immune activation.
- Trial name
- NCT07286487
- Testing
- SLS induced irritation, No Treatment, Low Dose Glycyrrhetinic Acid Formulation
- Where
- Croatia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Split, School of Medicine
Ulcerative Colitis
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior filgotinib treatment study in ulcerative…
- Trial name
- SELECTIONLTE (NCT02914535)
- Testing
- Filgotinib
- Where
- 323 sites in United States, Argentina and 37 more
- Volunteers
- 1,173 people
- Sponsor
- Alfasigma S.p.A.
Skin Barrier Function, Skin Hydration
Study of a Peptide Cream's Effect on the Facial Skin Barrier Using a Side-by-Side Comparison
The goal of this clinical trial is to evaluate whether a topical face cream containing the peptide Acetyl Hexapeptide-37 improves skin hydration and strengthens the skin barrier compared to a placebo cream in healthy adult…
- Conditions
- Skin Barrier Function, Skin Hydration, Topical Peptide Effects on Facial Skin Barrier Function
- Trial name
- NCT07548424
- Testing
- Acetyl Hexapeptide-37 Cream
- Where
- Croatia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Split, School of Medicine
Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
This study will test how well a new medicine called concizumab works in the body of people with haemophilia A or B without inhibitors. The purpose is to show that concizumab can prevent bleeds in the body and is safe to use.
- Trial name
- explorer8 (NCT04082429)
- Testing
- Concizumab
- Where
- 113 sites in United States, Algeria and 31 more
- Volunteers
- 156 people
- Sponsor
- Novo Nordisk A/S
Postoperative Complications
Bioelectrical Response to Preoperative Hydration in Colorectal Surgery
This single-center study will evaluate whether short-term changes in bioelectrical impedance measurements after a standardized preoperative intravenous fluid infusion can help predict complications following elective colon or…
- Trial name
- BIA-HYD-CRC (NCT07823530)
- Testing
- Ionolyte Balanced Isotonic Crystalloid
- Where
- Croatia
- Volunteers
- 120 people
- Sponsor
- University Hospital of Split